614 articles – 3073 Notices  [english version]
HAL : hal-00453293, version 1

Fiche détaillée  Récupérer au format
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 20, 12 (2006) 2155-61
Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study.
N. Vey, X. Thomas1, C. Picard2, T. Kovascovicz, C. Charin, J. M. Cayuela, H. Dombret, N. Dastugue, F. Huguet3, C. Bastard, A. Stamatoulas, M. Giollant, O. Tournilhac, E. Macintyre, A. Buzyn, D. Bories, M. Kuentz4, F. Dreyfus4, A. Delannoy5, S. Raynaud6, N. Gratecos4, Dominique Bordessoule7, 8, 9, 10, S. De Botton, C. Preudhomme11, O. Reman, X. Troussard, A. Pigneux, C. Bilhou, J. P. Vernant, C. Boucheix12, J. Gabert13,

Adult patients with acute lymphoblastic leukemia (ALL) and t(1;19)/E2A-PBX1 or t(4;11)/MLL-AF4 have a poor outcome. We have evaluated the impact of an intensified post-remission therapy using a high-dose chemotherapy course followed by allogeneic or autologous SCT on the outcome of 58 patients with t(1;19)/E2A-PBX1 (E2A group, n=24) or t(4;11)/MLL-AF4 (MLL group, n=34) treated in the LALA-94 multicenter prospective study. Patients in the MLL group had higher WBC counts and more frequent DIC. CR rates achieved by MLL and E2A groups were similar to other B-cell ALL (87, 82 and 86% respectively). While in CR, patients with a donor were assigned to alloSCT (n=22), the remaining patients with were randomized between autoSCT (n=15) or chemotherapy (n=8). Five-year overall survival was 31 and 45% for E2A and MLL groups, respectively. In both groups, DFS was higher in the alloSCT arm as compared to autoSCT and chemotherapy arms. The results of this study show that chemotherapy intensification did not overcome the poor prognosis of adults with t(1;19)/E2A-PBX1. Allogeneic SCT should thus be offered in first CR to patients with t(1;19)/E2A-PBX1 or t(4;11)/MLL-AF4. New therapeutic approaches are needed for patients without donor.
1 :  Laboratoire de Chimie et Biochimie des Substances Naturelles
2 :  Danone Research
3 :  Recherche & Développement
4 :  Service greffe de moelle osseuse
5 :  GANIL - Grand Accélérateur National d'Ions Lourds
6 :  Laboratoire d'oncohématologie
7 :  Laboratoire d'hématologie
8 :  Service d'Hématologie Clinique et thérapie cellulaire
9 :  Faculté de Médecine
10 :  PMRIL - Physiologie moléculaire de la réponse immune et des lymphoproliférations
11 :  Laboratoire d'Hématologie
12 :  Différenciation hématopoïétique normale et leucémique
13 :  IBCP - Institut de biologie et chimie des protéines [Lyon]
Sciences du Vivant/Immunologie